Bluebird Bio | BLUE - Passivo Circulante



Passivo Circulante Alterar Data
Agios Pharmaceuticals USD 82.21M 7.45M 2025-12
Alnylam Pharmaceuticals USD 1.47B 89.13M 2025-12
Amgen USD 25.49B 3.7B 2025-12
Arrowhead Research USD 347.42M 151.94M 2025-12
Biogen USD 3.35B 59.4M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
Incyte USD 1.52B 176.44M 2025-12
Ionis Pharmaceuticals USD 783M 120.46M 2025-12
Moderna USD 1.99B 306M 2025-12
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Novartis USD 27.28B 4.72B 2025-12
Pfizer USD 36.6B 1.13B 2025-09
PTC Therapeutics USD 968.43M 102.18M 2025-12
Regeneron Pharmaceuticals USD 4.37B 56.7M 2025-12
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
Tectonic Therapeutic USD 9.67M 293K 2025-12
Ultragenyx Pharmaceutical USD 340.02M 46.78M 2025-09
Vertex Pharmaceuticals USD 3.86B 614.1M 2025-12